Natus Medical Incorporated (NTUS): Price and Financial Metrics


Natus Medical Incorporated (NTUS): $26.70

0.63 (+2.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NTUS POWR Grades


  • NTUS scores best on the Growth dimension, with a Growth rank ahead of 99.3% of US stocks.
  • NTUS's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
  • NTUS's current lowest rank is in the Momentum metric (where it is better than 49.3% of US stocks).

NTUS Stock Summary

  • For NTUS, its debt to operating expenses ratio is greater than that reported by just 19.49% of US equities we're observing.
  • With a year-over-year growth in debt of -56.53%, Natus Medical Inc's debt growth rate surpasses merely 6.59% of about US stocks.
  • Over the past twelve months, NTUS has reported earnings growth of -205.3%, putting it ahead of only 10.07% of US stocks in our set.
  • Stocks that are quantitatively similar to NTUS, based on their financial statements, market capitalization, and price volatility, are OSPN, CLNE, SPRT, NGS, and HBIO.
  • Visit NTUS's SEC page to see the company's official filings. To visit the company's web site, go to www.natus.com.

NTUS Valuation Summary

  • In comparison to the median Healthcare stock, NTUS's EV/EBIT ratio is 311.24% lower, now standing at -56.4.
  • Over the past 243 months, NTUS's price/sales ratio has gone down 5.9.
  • NTUS's EV/EBIT ratio has moved up 110.8 over the prior 243 months.

Below are key valuation metrics over time for NTUS.

Stock Date P/S P/B P/E EV/EBIT
NTUS 2018-04-02 2.2 2.6 -53.8 224.8
NTUS 2011-11-29 1.0 0.9 21.4 14.1
NTUS 2009-11-12 2.5 1.7 30.5 18.6
NTUS 2009-07-01 2.0 1.4 20.6 10.7
NTUS 2007-07-06 3.5 3.4 65.4 34.4
NTUS 2005-11-08 7.5 5.4 76.7 60.0

NTUS Growth Metrics

  • Its 3 year cash and equivalents growth rate is now at -34.28%.
  • Its 3 year price growth rate is now at -16.26%.
  • Its 5 year price growth rate is now at -50.43%.
Over the past 30 months, NTUS's revenue has gone down $100,111,000.

The table below shows NTUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 421.228 41.767 -10.62
2020-12-31 415.684 34.426 -16.613
2020-09-30 428.382 29.248 -20.135
2020-06-30 449.042 45.625 -2.358
2020-03-31 489.801 70.929 10.733
2019-12-31 495.175 60.06 -15.671

NTUS Price Target

For more insight on analysts targets of NTUS, see our NTUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.00 Average Broker Recommendation 2 (Hold)

NTUS Stock Price Chart Interactive Chart >

Price chart for NTUS

NTUS Price/Volume Stats

Current price $26.70 52-week high $29.70
Prev. close $26.07 52-week low $16.38
Day low $26.07 Volume 115,500
Day high $26.75 Avg. volume 183,626
50-day MA $26.61 Dividend yield N/A
200-day MA $24.50 Market Cap 909.88M

Natus Medical Incorporated (NTUS) Company Bio


Natus Medical is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company was founded in 1987 and is based in Pleasanton, California.


NTUS Latest News Stream


Event/Time News Detail
Loading, please wait...

NTUS Latest Social Stream


Loading social stream, please wait...

View Full NTUS Social Stream

Latest NTUS News From Around the Web

Below are the latest news stories about Natus Medical Inc that investors may wish to consider to help them evaluate NTUS as an investment opportunity.

Natus Medical to Hold 2021 Second Quarter Financial Results Conference Call on August 6th

PLEASANTON, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 second quarter financial results after the close of the market on Thursday, August 5th. Natus management will host a conference call on Friday, August 6th at 8:

Yahoo | July 1, 2021

Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson

PLEASANTON, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced Dr. Barbara Paul, the Chairperson of the Board of Directors will retire from the Board effective June 30, 2021. The Board has elected independent director Joshua Levine who has served on the Natus boar

Yahoo | June 28, 2021

Shareholders May Not Be So Generous With Natus Medical Incorporated's (NASDAQ:NTUS) CEO Compensation And Here's Why

Shareholders of Natus Medical Incorporated ( NASDAQ:NTUS ) will have been dismayed by the negative share price return...

Yahoo | June 10, 2021

Natus Medical (NTUS) Surges 6.6%: Is This an Indication of Further Gains?

Natus Medical (NTUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | April 27, 2021

15 Best Small-Cap Healthcare Stocks to Buy

In this article, we present the 15 Best Small-Cap Healthcare Stocks to Buy. If you’re in a hurry, click to skip ahead and see the 5 Best Small-Cap Healthcare Stocks to Buy. The term small cap can be used to define established companies with a small market capitalization ranging anywhere between $300 million and $2 […]

Yahoo | February 14, 2021

Read More 'NTUS' Stories Here

NTUS Price Returns

1-mo 3.85%
3-mo 0.60%
6-mo 5.83%
1-year 43.70%
3-year -27.84%
5-year -30.56%
YTD 33.23%
2020 -39.25%
2019 -3.06%
2018 -10.92%
2017 9.77%
2016 -27.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.806 seconds.